AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04769206 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS 7000
Description: The FDA-approved TENS 7000 device will be used for Trans-auricular vagus nerve stimulation (TaVNS) during a period of enhanced vascular oxidative stress. This device will be supplemented with ear clip electrodes. The site of the stimulation for such electrodes are the tragus or concha. The device will have built in safety controls to minimize additional risks to the subjects (as per FDA guidance on stimulators). We will use typical stimulation conditions (30 Hz, 300 µs) and amplitude dependent on perception threshold.
Study NCT06154447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-828
Description: Suspension for Oral Administration
Study NCT06272825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: VR-based exercise program will be applied in addition to the conventional rehabilitation program, 5 days a week for a total of 3 weeks.
Study NCT06272825 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional rehabilitation
Description: The conventional exercise program will include 20 minutes(Transcutaneous Electrical Nerve Stimulation) TENS with conventional method, 4 minutes continue ultrason, 20 minutes hot pack.
Study NCT06272825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional rehabilitation
Description: The conventional exercise program will include 20 minutes(Transcutaneous Electrical Nerve Stimulation) TENS with conventional method, 4 minutes continue ultrason, 20 minutes hot pack.
Study NCT05720429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducational program
Description: A psychoeducational program consisting of 11 one-hour sessions, with a weekly or biweekly frequency, each one regarding specific tools and skills to promote emotional well-being, self-care, and the ability to deal with stressful situations. They are conducted by community psychologists, who will give a brief theoretical introduction and then conduct practical group exercises that apply the concepts introduced. Every session ends with a relaxation exercise and some habits that the participants can incorporate into their daily life.~Session Index: (1) Emotional management;(2) Thought management; (3) Stress management; (4) Communication skills, active listening, and empathy; (5) Self-care; (6) Individual/group self-esteem; (7) Anxiety/coping with panic. Mindfulness; (8) Activating motivation; (9) Problem-Solving; (10) Positive psychology and emotional intelligence; (11) Emotional expression through art.
Study NCT05022888 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: regional tissue saturation
Description: tissue oxygen saturation measured from 4 different regions defined on the trapezius muscle. The NIRS probe will be used in these areas.
Study NCT04855331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic pancreatoduodenectomy
Description: Laparoscopic pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
Study NCT04855331 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open pancreatoduodenectomy
Description: Open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
Study NCT05401461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evening mobilisation
Description: Evening mobilisation delivered between (19.00 and 21.00) according to standardised procedures and established safety criteria. The intervention will begin on day 1 of admission or the first evening following recruitment. Mobilisation will be defined as a score of ≥ 2 on the Manchester mobility score (sit on the edge of the bed or higher), with actual mobilisation level achieved and duration of intervention based on clinical decision of the mobilisation therapists. Patients will also be offered the opportunity to engage in activities which may be part of their normal evening routines (e.g. brushing teeth, reading or watching television). The intervention will be carried out for up to seven consecutive evenings. The evening mobilisation will be delivered in addition to any input from the MDT during normal daily working hours and will not replace any standard therapy.
Study NCT05730855 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Real-time Polymerase Chain Reaction technique
Description: Real-time Polymerase Chain Reaction technique
Study NCT03883763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine S75:R25 plus 8% glucose
Description: Spinal anesthesia, 20 mg
Study NCT03883763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine S50:R50 plus 8% glucose
Description: Spinal anesthesia, 20 mg
Study NCT05226117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Sacituzumab govitecan is a humanized monoclonal antibody (mAb) with a hydrolyzable linker through which SN-38 is conjugated to the humanized mAb hRS7 IgG1κ to enhance the delivery of SN-38 to Trop-2- expressing tumors while reducing systemic toxicity. SN-38 is the active metabolite of irinotecan. Sacituzumab govitecan is administered at 10 mg/kg as an IV infusion on days 1 and 8 of a 21- day cycle till progression, toxicity or withdrawal of consent
Study NCT05002504 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: A series of questions were asked to the children's parents in a virtual questionnaire
Description: A series of questions were asked to the children's parents in a virtual questionnaire on physical characteristics, previous health assessments and observations of their balance and coordination in front of their children
Study NCT05002504 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: A series of questions were asked to the children's parents in a virtual questionnaire
Description: A series of questions were asked to the children's parents in a virtual questionnaire on physical characteristics, previous health assessments and observations of their balance and coordination in front of their children
Study NCT05002504 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: A series of questions were asked to the children's parents in a virtual questionnaire
Description: A series of questions were asked to the children's parents in a virtual questionnaire on physical characteristics, previous health assessments and observations of their balance and coordination in front of their children
Study NCT05002504 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI)
Description: the school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which evaluates five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-49%), normal (50-79%) and high (80-100%). Low and high values are considered impairments in one or more of the areas evaluated. Evaluation of the Battelle scale was carried out before and after the therapy sessions.
Study NCT05002504 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI)
Description: the school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which evaluates five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-49%), normal (50-79%) and high (80-100%). Low and high values are considered impairments in one or more of the areas evaluated. Evaluation of the Battelle scale was carried out before and after the therapy sessions.
Study NCT05002504 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI)
Description: the school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which evaluates five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-49%), normal (50-79%) and high (80-100%). Low and high values are considered impairments in one or more of the areas evaluated. Evaluation of the Battelle scale was carried out before and after the therapy sessions.
Study NCT05002504 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapy sessions
Description: Seven treatment sessions were carried out with the balance and coordination therapeutic exercise techniques (group 3) most frequently used for the treatment of these pathologies; seven sessions of craniosacral therapy (group 2) as corrective and preventive in possible alterations during infant neurodevelopment and finally seven sessions simulating craniosacral therapy on a placebo group (group 1) as a control of the treatments used.
Study NCT05002504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapy sessions
Description: Seven treatment sessions were carried out with the balance and coordination therapeutic exercise techniques (group 3) most frequently used for the treatment of these pathologies; seven sessions of craniosacral therapy (group 2) as corrective and preventive in possible alterations during infant neurodevelopment and finally seven sessions simulating craniosacral therapy on a placebo group (group 1) as a control of the treatments used.
Study NCT05002504 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Therapy sessions
Description: Seven treatment sessions were carried out with the balance and coordination therapeutic exercise techniques (group 3) most frequently used for the treatment of these pathologies; seven sessions of craniosacral therapy (group 2) as corrective and preventive in possible alterations during infant neurodevelopment and finally seven sessions simulating craniosacral therapy on a placebo group (group 1) as a control of the treatments used.
Study NCT05054816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational adaptive directional microphone strategy
Description: A receiver-in-canal hearing aid developed by the Study Sponsor used with the investigational adaptive directional microphone strategy that is expected to improve sound quality of speech in a car.
Study NCT05054816 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator omnidirectional microphone strategy
Description: A receiver-in-canal hearing aid developed by the Study Sponsor used with the comparator omnidirectional microphone strategy that is used with the default settings as specified in the manufacturer's fitting software.
Study NCT06154447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension for Oral Administration
Study NCT06154447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Solution for Oral Administration
Study NCT06154447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Syrup for Oral Administration
Study NCT06154447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezacaftor
Description: Tablets for Oral Administration
Study NCT06154447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-118
Description: Tablets for Oral Administration
Study NCT05054816 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator fixed directional microphone strategy
Description: A receiver-in-canal hearing aid developed by the Study Sponsor used with the comparator fixed directional microphone strategy that is used with the default settings as specified in the manufacturer's fitting software.
Study NCT06154447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension and Tablets for Oral Administration
Study NCT04794517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10Mg Tab
Description: Dapagliflozin 10 mg/die will be administered orally for six-weeks.
Study NCT04794517 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one tablet/die will be administered orally for six-weeks.
Study NCT06612294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEF Interventional Session
Description: 3 sessions over 6 weeks for asthma management
Study NCT06612294 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Sessions
Description: 3 sessions over 6 weeks for asthma management
Study NCT06612294 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Booster
Description: A single booster session after the 6-months assessments are completed.
Study NCT06612294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Booster
Description: A single booster session after the 6-months assessments are completed.
Study NCT06612294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active booster
Description: A single booster session after the 6-months assessments are completed.
Study NCT06524154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: positive reinforcement
Description: normal treatment with with praising the child with encouraging words and pleasing smiles.
Study NCT06524154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rewarding
Description: normal treatment with giving simple gifts like stickers at the end of the procedure.
Study NCT06524154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingent escape
Description: normal treatment with giving some rest of the procedure while the child on the chair.
Study NCT06236113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution
Description: administered at rate of 0.1 mg/kg/hr
Study NCT06236113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution
Description: administered at rate of 0.1 mg/kg/hr
Study NCT04758247 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TheraNova Neuromodulation System
Description: The investigational device is a transcutaneous electrical nerve stimulation (TENS) device that is designed to provide stimulation to the nerves at the site of application via surface electrodes temporarily adhered to the skin.
Study NCT04758247 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TheraNova Neuromodulation System
Description: The investigational device is a transcutaneous electrical nerve stimulation (TENS) device that is designed to provide stimulation to the nerves at the site of application via surface electrodes temporarily adhered to the skin.
Study NCT06372314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN): this is total nutrition provided by central vein.
Description: isoleucine, leucine, valine and tryptophan intakes will be varied in the TPN solutions to study the requirements for each of these amino acids in neonates that are TPN fed.
Study NCT05436639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-62 dose
Description: SPI-62 is an 11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor, supplied as oral tablets for dose 2 of drug (2mg).
Study NCT05309694 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Paragard® T380A Intrauterine Copper Contraceptive with New Inserter
Description: Paragard® IUS with Investigational Inserter combines the current insertion tube and white rod to form a new pre-assembled inserter device that supports a single hand operation.~The device is used to pass the IUS through the cervical canal and into the uterine cavity and facilitates insertion of the T shaped Paragard® IUS implant into the uterus.
Study NCT05727748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal exercise with augmented reality
Description: The intervention program has a duration of 12 weeks with 3 sessions per week of 60 minutes each. The multimodal group with augmented reality was divided into 4 sub-groups. The session consisted of six stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed). Four stations are the same of the previous group and the other 2 stations are with augmented reality. These 2 stations worked the same cognitive and physical components but through the portable exergame platform for the elderly.
Study NCT05727748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal exercise
Description: The intervention program has a duration of 12 weeks with 3 sessions per week of 60 minutes each. The multimodal group was divided into 2 sub-groups. The session consisted of four stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed).~The session consisted of six stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed).
Study NCT05727748 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The control group continued their daily activities for 12 weeks and did not participate in any new physical activity program during the study.
Study NCT05991583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBB0979
Description: IBB0979 should be subcutaneous injected，qw
Study NCT04221750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle therapy
Description: Weight management program, in which participants are prescribed a balanced diet that provides and energy deficit of 500 to 750 kcal per day to induced \~10% weight loss plus Supervised combined aerobic and resistance exercise training three times weekly
Study NCT04221750 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle therapy
Description: Weight management program, in which participants are prescribed a balanced diet that provides and energy deficit of 500 to 750 kcal per day to induced \~10% weight loss plus Supervised combined aerobic and resistance exercise training three times weekly
Study NCT04221750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of metformin will be increased to 1000 mg (two tablets) daily. After another week, the dose of metformin will be increased to 1500 mg (three tablets) daily.
Study NCT04221750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of metformin will be increased to 1000 mg (two tablets) daily. After another week, the dose of metformin will be increased to 1500 mg (three tablets) daily.
Study NCT04221750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of placebo will be increased to 1000 mg (two tablets) daily. After another week, the dose of placebo will be increased to 1500 mg (three tablets) daily.
Study NCT04221750 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Lifestyle
Description: Group educational sessions that focus on healthy diet, exercise, and social support once a month
Study NCT05676944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Labyrinth Devices MVI™ Multichannel Vestibular Implant System
Description: Unilateral implantation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System receiver/stimulator including insertion of electrode arrays in the semicircular canal ampullae of the inner ear, followed by motion-modulated prosthetic electrical stimulation.
Study NCT05129969 — intervention group
Intervention type: OTHER
Intervention: Physician's choice according to patient's needs.
Description: Routine care as per site standard.
Study NCT06332352 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: Intra-articular hip injection of PRP, Blood Collection 45mL, Processed Neutrophil-Poor PRP, 1 injection to one hip joint.
Study NCT06636734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06636734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT06636734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: Given PO
Study NCT06636734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06636734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT06636734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT04647786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype medical device (SEA CtV)
Description: A prototype device that delivers a controlled flow of gas to the upper airways via the subglottic suction port of an established tracheostomy tube. Gas flow may be timed, warmed and/or humidified.
Study NCT06425211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic exercises
Description: Recognition of the pelvic area, respiratory management, lumbo-pelvic mobilization, discrimination of abdomino-pelvic contraction and myofascial release techniques.